ZYXI

Zynex Inc

Add to Watchlist

Advanced Chart

1.040

-0.01(-0.952%)1D

Line

Candle

YTD

High

1.100

Open

1.030

VWAP

1.05

Vol

133.82K

Mkt Cap

31.51M

Low

1.030

Amount

141.06K

EV/EBITDA(TTM)

Total Shares

31.78M

74.34M

EV/OCF(TTM)

P/S(TTM)

0.23

Zynex, Inc. is a medical technology company specialized in the manufacturing and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring. The Company’s devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Company’s products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave, M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Private Labeled Rehabilitation Products, which include Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces, Bracing (Knee and Wrist), and Dynacomp, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter, and HemeOx tHb Oximeter.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

22.71M

-54.54%

-0.173

-347.61%

23.18M

-49.58%

-0.153

+666.65%

23.92M

-10.01%

-0.140

-57.58%

Estimates Revision

The market is revising No Change the revenue expectations for Zynex, Inc. (ZYXI) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -28.28%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-28.28%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast ZYXI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZYXI is 3.70 USD with a low forecast of 3.70 USD and a high forecast of 3.70 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 1.040

Low

3.70

Averages

3.70

High

3.70

Current: 1.040

Low

3.70

Averages

3.70

High

3.70

H.C. Wainwright

Yi Chen

Buy -> Neutral

downgrade

2025-08-01

Reason

H.C. Wainwright

Yi Chen

Price Target

2025-08-01

downgrade

Buy -> Neutral

Reason

H.C. Wainwright analyst Yi Chen downgraded Zynex to Neutral from Buy without a price target. The company reported a Q2 miss and an operational restructuring is in progress, the analyst tells investors in a research note. The firm says there is no visibility at this point as to when Tricare payments to Zynex will resume.

Ladenburg

Neutral -> Buy

upgrade

$3.70

2025-08-01

Reason

Ladenburg

Price Target

$3.70

2025-08-01

upgrade

Neutral -> Buy

Reason

Ladenburg upgraded Zynex to Buy from Neutral with a $3.70 price target.

Ladenburg

Neutral -> Buy

upgrade

$3.70

2025-08-01

Reason

Ladenburg

Price Target

$3.70

2025-08-01

upgrade

Neutral -> Buy

Reason

As previously reported, Ladenburg upgraded Zynex to Buy from Neutral with a $3.70 price target. While the firm recognizes disruptions in the pain segment are "material," creating uncertainty and negatively impacting the company's performance, it argues that the opportunity for the NiCO laser pulse oximeter "should not be overlooked," citing the differentiated technology and agency-driven efforts to provide more equitable care.

RBC Capital

Sector Perform

downgrade

$4 -> $3

2025-07-15

Reason

RBC Capital

Price Target

$4 -> $3

2025-07-15

downgrade

Sector Perform

Reason

RBC Capital lowered the firm's price target on Zynex to $3 from $4 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 results for MedTech names. Based on the firm's intra-quarter diligence with key opinion leaders and company management / investor discussions, there is a high level of interest in MedTech and multiple opportunities across the sector, the analyst tells investors in a research note. Regarding the company however, the firm notes that sentiment on the stock is quite negative given its Q1 miss and no guidance issued for 2025.

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$17 → $15

2025-03-12

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$17 → $15

2025-03-12

Maintains

Strong Buy

Reason

Ladenburg Thalmann

Jeffrey Cohen

Strong Buy

Hold

Downgrades

n/a

2025-03-12

Reason

Ladenburg Thalmann

Jeffrey Cohen

Price Target

n/a

2025-03-12

Downgrades

Strong Buy

Hold

Reason

Ladenburg downgraded Zynex to Neutral from Buy without a price target saying the company continues to adjust operationally amid revenue pressure.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Zynex Inc (ZYXI.O) is -1.90, compared to its 5-year average forward P/E of 22.44. For a more detailed relative valuation and DCF analysis to assess Zynex Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

22.44

Current PE

-1.90

Overvalued PE

36.92

Undervalued PE

7.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

11.81

Current EV/EBITDA

-6.33

Overvalued EV/EBITDA

21.03

Undervalued EV/EBITDA

2.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

1.98

Current PS

1.13

Overvalued PS

3.01

Undervalued PS

0.95

Financials

Annual

Quarterly

FY2025Q2

YoY :

-55.32%

22.29M

Total Revenue

FY2025Q2

YoY :

-561.95%

-10.28M

Operating Profit

FY2025Q2

YoY :

-1746.10%

-20.03M

Net Income after Tax

FY2025Q2

YoY :

-1750.00%

-0.66

EPS - Diluted

FY2025Q2

YoY :

-724.77%

-6.23M

Free Cash Flow

FY2025Q2

YoY :

-14.57%

68.35

Gross Profit Margin - %

FY2025Q2

YoY :

-159.75%

-5.30

FCF Margin - %

FY2025Q2

YoY :

-3783.20%

-89.87

Net Margin - %

FY2025Q2

YoY :

-100.00%

N/A

ROIC

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

71.5K

USD

0-12

Months

236.4K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

71.5K

USD

0-12

Months

236.4K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ZYXI News & Events

Events Timeline

2025-08-18 (ET)

2025-08-18

08:17:30

Zynex Reveals Newly Appointed Executive Team

2025-07-31 (ET)

2025-07-31

16:16:04

Zynex suspends guidance

2025-07-31

16:14:51

Zynex reports Q2 EPS (66c) with items vs. 4c last year

News

7.0

09-27Globenewswire

ZYNEX INVESTIGATION NOTICE: Bragar Eagel & Squire, P.C. is Looking into Zynex, Inc. for Long-Term Shareholders and Urges Investors to Reach Out to the Firm

7.0

09-09Globenewswire

ZYNEX UPDATE: Bragar Eagel & Squire, P.C. Launches Investigation into Zynex, Inc. for Long-Term Shareholders and Urges Investors to Reach Out to the Firm